Market closed

Alnylam Pharmaceuticals/$ALNY

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Ticker

$ALNY
Trading on

Industry

Biotechnology

Employees

2,100

ALNY Metrics

BasicAdvanced
$32B
Market cap
-
P/E ratio
-$2.62
EPS
0.39
Beta
-
Dividend rate
$32B
0.39
$296.59
$141.98
948K
2.749
2.568
8,016.112
8,426.139
-1.40%
-2.92%
497.73%
15.057
990.74
990.74
1,963.553
21.54%
-36.29%
40.87%
-28.37%

What the Analysts think about ALNY

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.

ALNY Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALNY Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALNY

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals (ALNY) has a market cap of $32B as of November 21, 2024.

What is the P/E ratio for Alnylam Pharmaceuticals stock?

The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of November 21, 2024.

Does Alnylam Pharmaceuticals stock pay dividends?

No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of November 21, 2024.

When is the next Alnylam Pharmaceuticals dividend payment date?

Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.

What is the beta indicator for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.